Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiac Arrhythmia, Neurological Disorders, and Cytoskeletal Organization Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ANK2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANK2 Recombinant & Mutant Protein (Domain-specific: MBD (aa 1-189), SBD (aa 409-873), DD, RD). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 or E.coli expressed available. | View ANK2 Products |
| Gene Delivery | ANK2 Promise-ORF / Lentivirus. Full-length ORF (NM_001148) for stable cell lines. High titer (>10^8 TU/ml). Endotoxin Controlled. | View ANK2 Products |
| Benchmark Ab | Anti-ANK2 Recombinant Antibody. Positive control for Western Blot, ICC, IHC, and Immunoprecipitation. | View ANK2 Products |
| Validator | ANK2 siRNA Set (3 unique sequences). For knockdown verification. Sequence-verified, endotoxin-controlled. | View ANK2 Products |
| Related Target A | SCN5A (Nav1.5). Core ion-channel partner; convergence point for arrhythmia therapeutics. | View SCN5A Products |
| Related Target B | SPTBN1 (Spectrin Beta Non-Erythrocytic 1). Cytoskeletal scaffold partner essential for ANK2 membrane anchoring. | View SPTBN1 Products |
| Related Target C | SLC8A1/NCX1. Critical calcium-handling partner of ANK2 in cardiomyocytes. | View SLC8A1 Products |
| Related Target D | RYR2. Co-regulated in calcium channel scaffolding and arrhythmia pathology. | View RYR2 Products |
| Related Target E | ATP2B4 (PMCA4b). ANK2-regulated calcium extrusion machinery component. | View ATP2B4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Large multi-domain intracellular scaffold; difficult full-length expression | HEK293-expressed domain constructs (MBD, SBD, DD, RD) with Sequence Verified purity >95%; Isoform-specific constructs (ANK2-B cardiac, ANK2-R neuronal) also available. |
| Disease mutant mechanism validation (Loss-of-function / dominant-negative effects) | High-purity WT and point-mutant proteins (e.g., E1425G, L1622P, R1988W); Theoretical MW confirmed by SEC-MALS/SDS-PAGE. |
| Intracellular PPI screening (e.g., ANK2-SCN5A, ANK2-SPTBN1) | Stable cell lines via Lentivirus for BiFC, Co-IP, and FRET-based assays; purified domain fragments with distinct tags (His, GST) for SPR/BLI. |
| Paralog off-target risk (ANK1 / ANK3) | Human ANK1/ANK3 ortholog domain proteins available for cross-screening (>95% purity) to ensure selectivity. |
| Lack of controls / false positives in PPI assays | Clinical Benchmark Antibody, Validated siRNA, and Endotoxin Controlled (<1EU/ug) proteins included for specificity checks. |
| Cardiac vs Neuronal Isoform Studies | Isoform-specific constructs (ANK2-B, ANK2-R) with >95% purity for tissue-selective screening. |
Live ANK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Cardiac Arrhythmia & Neurological Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
ANK2 (Ankyrin-B) is a genetically validated intracellular scaffold whose dysfunction underpins Long QT syndrome type 4 (LQT4) and a spectrum of neurological phenotypes. The therapeutic landscape is transitioning from discovery-phase academic research toward targeted precision medicine strategies. First-generation approaches center on small-molecule protein-protein interaction (PPI) stabilizers and pharmacological chaperones to rescue trafficking-deficient mutants (e.g., E1425G, L1622P). Concurrently, gene therapy (AAV/Lentivirus) and nucleic acid modalities (ASO/siRNA) are being explored for loss-of-function alleles, with AAV-based gene replacement entering preclinical efficacy modeling in human iPSC-cardiomyocytes. As the field converges on rare-channelopathy indications, demand for domain-specific biochemical assays, isoform-selective reagents, and isogenic cell-line models is accelerating.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/Lentivirus) | Academic Consortia (Duke, Chicago), Early-stage Biotech | LQT4, Congenital Heart Disease, Autism Spectrum | Full-length ANK2 Lentivirus for preclinical efficacy modeling in human cardiomyocytes; sequence-verified ORF control. |
| Small-Molecule PPI Modulator / Pharmacological Chaperone | Academic consortia (Univ. of Iowa, Duke), Novartis, Pfizer, Rare-disease biotechs | Long QT Syndrome, Cardiac Arrhythmias, Trafficking-deficient mutants (E1425G, L1622P) | Domain-specific SPR / AlphaScreen / Thermal Shift Assay with high-purity ANK2 WT and mutant proteins. |
| ASO / RNAi | Rare Disease Focused Companies | Neurodevelopmental Disorders, Cancer (Emerging) | Validated siRNA sets for knockdown efficacy validation; ANK2-overexpressing cell lines. |
| Peptide / Biologic Intracellular Inhibitors | University spin-offs | Competitive inhibition of ANK2-SCN5A interaction | Spectrin-binding domain (SBD) constructs for displacement assay development; cell-penetration assays. |